© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 5, 394-398,
March 3, 1993
© 1993 Oxford University Press
Xenografts of Primary Human Prostatic Carcinoma
Institute of Pathology, Case Western Reserve University School of Medicine Cleveland, Ohio.
Department of Medicine, Case Western Reserve University School of Medicine Cleveland, Ohio.
Department of Urology, Case Western Reserve University School of Medicine Cleveland, Ohio.
Department of Genetics, Case Western Reserve University School of Medicine Cleveland, Ohio.
Department of Pathology, Wayne State University School of Medicine Detroit, Mich.
Correspondence to: Thomas G. Pretlow, M.D., Institute of Pathology B–30, Case Western Reserve University, 2085 Adelbert Rd., Cleveland, OH 44106.
Background: Prostatic carcinoma is both the most common invasive cancer and the second most common cause of cancer deaths in men in the United States. Before 1991, attempts to propagate prostatic carcinoma from primary tumors for periods longer than 3 months were unsuccessful in vivo and in vitro with rare exceptions. In 1991, we reported establishment of slowly growing tumors for six of 10 human primary prostatic carcinomas approximately 2–6 months after transplantation. However, none of the tumors were larger than 5 mm or serially transplantable. Purpose: Our purpose in this study was to determine whether human primary prostatic carcinoma could be grown as serially transplantable xenografts. Methods: Cells from primary prostatic carcinomas obtained from transurethral prostatic resections or total prostatectomies in 20 patients were injected subcutaneously into male nude mice on the day of surgery. Sustained-release testosterone pellets were placed subcutaneously in the mice 2–24 days before transplantation of tumors and at intervals of 10–12 weeks. Serial transplantations in subsequent generations of mice were carried out by similar methods. Chromosome analysis was performed on six tumors. Results: Six of 20 primary prostatic carcinomas have grown sufficiently to permit serial transplantation into second mice; four have been documented histopathologically in the second mouse and serially transplanted into three or more successive mice. When a single primary tumor was injected into several mice by the same procedure, tumors failed to grow in some recipients but became serially transplantable in others. Growth of these tumors is slow and irregular, with frequent regressions. Short-term cultures of 10 tumors, eight of which were injected into mice in parallel, were initiated on the day of surgery; CWR31, which was successfully transplanted serially, exhibited only aberrant metaphases and showed clonal, chromosomal changes in culture. Including CWR31, three of the six tumors for which chromosomal analysis was successful contained clonal aberrations. Preliminary studies of SCID (severe combined immunodeficient) mice suggest that they are not superior to nude mice for establishment of serially transplantable prostatic carcinoma xenografts. Conclusions: A proportion of human primary prostatic carcinomas can be grown as xenografts. Four new serially transplantable xenografts (CWR21, CWR31, CWR91, and CWR22) are currently propagated in our laboratory, a resource that was not previously available. Implications: Our experience suggests that the most important factor in serial transplantation is the collaboration of urologists and pathologists in expediting placement of the tumor in cold saline, examination of the frozen section, and transplantation. [J Natl Cancer Inst 85:394–398, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Attar, M. Jure-Kunkel, A. Balog, M. E. Cvijic, J. Dell-John, C. A. Rizzo, L. Schweizer, T. E. Spires, J. S. Platero, M. Obermeier, et al. Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer Cancer Res., August 15, 2009; 69(16): 6522 - 6530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Knouf, M. J. Metzger, P. S. Mitchell, J. D. Arroyo, J. R. Chevillet, M. Tewari, and A. D. Miller Multiple Integrated Copies and High-Level Production of the Human Retrovirus XMRV (Xenotropic Murine Leukemia Virus-Related Virus) from 22Rv1 Prostate Carcinoma Cells J. Virol., July 15, 2009; 83(14): 7353 - 7356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dagvadorj, S.-H. Tan, Z. Liao, L. R. Cavalli, B. R. Haddad, and M. T. Nevalainen Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor Clin. Cancer Res., October 1, 2008; 14(19): 6062 - 6072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dagvadorj, S. Collins, J.-B. Jomain, J. Abdulghani, J. Karras, T. Zellweger, H. Li, M. Nurmi, K. Alanen, T. Mirtti, et al. Autocrine Prolactin Promotes Prostate Cancer Cell Growth via Janus Kinase-2-Signal Transducer and Activator of Transcription-5a/b Signaling Pathway Endocrinology, July 1, 2007; 148(7): 3089 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Williams, R. F. Merchant, E. Garrett-Mayer, J. T. Isaacs, J. T. Buckley, and S. R. Denmeade A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease J Natl Cancer Inst, March 7, 2007; 99(5): 376 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. You, X.-B. Shi, G. DuRaine, D. Haudenschild, C. G. Tepper, S. Hao Lo, R. Gandour-Edwards, R. W. de Vere White, and A. H. Reddi Interleukin-17 Receptor-Like Gene Is a Novel Antiapoptotic Gene Highly Expressed in Androgen-Independent Prostate Cancer Cancer Res., January 1, 2006; 66(1): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer Cancer Res., November 1, 2004; 64(21): 7995 - 8001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E.H. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol. Cancer Ther., August 1, 2004; 3(8): 921 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, T. J. Ahonen, K. Alanen, J. Xie, M. J. LeBaron, T. G. Pretlow, E. L. Ealley, Y. Zhang, M. Nurmi, B. Singh, et al. Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade Cancer Res., July 15, 2004; 64(14): 4774 - 4782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Ling, X. Wang, D. T. Lee, P.C. Tam, S.-W. Tsao, and Y.-C. Wong Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R) Carcinogenesis, April 1, 2004; 25(4): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Dyke, K. L. Zakian, W. M. Spees, C. Matei, Y. Chen, X. Mao, D. C. Shungu, and J. A. Koutcher Metabolic Response of the CWR22 Prostate Tumor Xenograft after 20 Gy of Radiation Studied by 1H Spectroscopic Imaging Clin. Cancer Res., October 1, 2003; 9(12): 4529 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes Cancer Res., May 15, 2003; 63(10): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Tepper, D. L. Boucher, P. E. Ryan, A.-H. Ma, L. Xia, L.-F. Lee, T. G. Pretlow, and H.-J. Kung Characterization of a Novel Androgen Receptor Mutation in a Relapsed CWR22 Prostate Cancer Xenograft and Cell Line Cancer Res., November 15, 2002; 62(22): 6606 - 6614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mendoza, G. L. Phillips, J. Silva, R. Schwall, and D. Wickramasinghe Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer Cancer Res., October 1, 2002; 62(19): 5485 - 5488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Fox, B. Higgins, K. M. Maiese, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, and D. B. Agus Antibody to Vascular Endothelial Growth Factor Slows Growth of an Androgen-independent Xenograft Model of Prostate Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3226 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mousses, L. Bubendorf, U. Wagner, G. Hostetter, J. Kononen, R. Cornelison, N. Goldberger, A. G. Elkahloun, N. Willi, P. Koivisto, et al. Clinical Validation of Candidate Genes Associated with Prostate Cancer Progression in the CWR22 Model System using Tissue Microarrays Cancer Res., March 1, 2002; 62(5): 1256 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kim, C. W. Gregory, F. S. French, G. J. Smith, and J. L. Mohler Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft Am. J. Pathol., January 1, 2002; 160(1): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Presnell, E. S. Werdin, S. Maygarden, J. L. Mohler, and G. J. Smith Establishment of Short-Term Primary Human Prostate Xenografts for the Study of Prostate Biology and Cancer Am. J. Pathol., September 1, 2001; 159(3): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Pinieux, M.-E. Legrier, F. Poirson-Bichat, Y. Courty, R. Bras-Goncalves, A.-M. Dutrillaux, F. Nemati, S. Oudard, R. Lidereau, P. Broqua, et al. Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach Am. J. Pathol., August 1, 2001; 159(2): 753 - 764. [Abstract] [Full Text]
|
|
|
|
|
|
M. Asamoto, N. Hokaiwado, Y.-M. Cho, S. Takahashi, Y. Ikeda, K. Imaida, and T. Shirai Prostate Carcinomas Developing in Transgenic Rats with SV40 T Antigen Expression under Probasin Promoter Control Are Strictly Androgen Dependent Cancer Res., June 1, 2001; 61(12): 4693 - 4700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Butler, D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H. T. Thaler, R. A. Rifkind, P. A. Marks, and V. M. Richon Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo Cancer Res., September 1, 2000; 60(18): 5165 - 5170. [Abstract] [Full Text]
|
|
|
|
|
|
T. G. Pretlow, S. Schwartz, J. M. Giaconia, A. L. Wright, H. A. Grimm, N. L. Edgehouse, J. R. Murphy, S. D. Markowitz, J. M. Jamison, J. L. Summers, et al. Prostate Cancer and Other Xenografts from Cells in Peripheral Blood of Patients Cancer Res., August 1, 2000; 60(15): 4033 - 4036. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. Holleran, C. J. Miller, and L. A. Culp Tracking Micrometastasis to Multiple Organs with lacZ-tagged CWR22R Prostate Carcinoma Cells J. Histochem. Cytochem., May 1, 2000; 48(5): 643 - 652. [Abstract] [Full Text]
|
|
|
|
|
|
A. Krishan, A. Oppenheimer, W. You, R. Dubbin, D. Sharma, and B. L. Lokeshwar Flow Cytometric Analysis of Androgen Receptor Expression in Human Prostate Tumors and Benign Tissues Clin. Cancer Res., May 1, 2000; 6(5): 1922 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Hubert, I. Vivanco, E. Chen, S. Rastegar, K. Leong, S. C. Mitchell, R. Madraswala, Y. Zhou, J. Kuo, A. B. Raitano, et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors PNAS, December 7, 1999; 96(25): 14523 - 14528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde, and H. I. Scher Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence J Natl Cancer Inst, November 3, 1999; 91(21): 1869 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bubendorf, M. Kolmer, J. Kononen, P. Koivisto, S. Mousses, Y. Chen, E. Mahlamaki, P. Schraml, H. Moch, N. Willi, et al. Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays J Natl Cancer Inst, October 20, 1999; 91(20): 1758 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Pretlow Re: Dietary Fat, Calories, and Prostate Cancer Risk J Natl Cancer Inst, October 6, 1999; 91(19): 1691a - 1692a. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a. Tan, Y. Sharief, K. G. Hamil, C. W. Gregory, D.-Y. Zang, M. Sar, P. H. Gumerlock, R. W. deVere White, T. G. Pretlow, S. E. Harris, et al. Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells Mol. Endocrinol., April 1, 1997; 11(4): 450 - 459. [Abstract] [Full Text]
|
|